Pharma & Biotech BioVie targets Parkinson’s at its source with lead drug bezisterim By Proactive 26/03
Medical technology & services Inside Biotech: 4DMedical’s Mayo moment sharpens US push — and investors take notice By Proactive 25/03
Mining Australia inflation steadies in February as core pressures ease ahead of geopolitical shock By Proactive 25/03
Archive CMA orders price caps and mandatory price lists for vets in sweeping market overhaul By Proactive 24/03
Tech Tech Bytes: OpenAI dangles guaranteed returns in high-stakes enterprise AI land grab By Proactive 24/03
Finance ASX 200 Hourly: ASX closes slightly higher after losing momentum: BHP exec call out Australia's competitiveness By Proactive 24/03
Agribusiness Replenish Nutrients builds a licensing flywheel to scale high-margin fertilizer IP By Proactive 24/03
Archive Polymarket bettors put 66% chance of US forces entering Iran by end of April By Proactive 23/03
Renewables & cleantech Australia’s oil shock exposure sharpens focus on transport electrification, IEEFA says By Proactive 23/03
Pharma & Biotech Inside Biotech: Big pharma splits its bets between certainty and risk By Proactive 23/03
Investments and investor services Frank Talk: Oil shock sends yields higher and gold lower By Proactive 20/03
Medical technology & services Inside Biotech: Cyberattacks expose healthcare’s growing digital fault lines By Proactive 19/03
Retail & consumer Australia's jobless rate climbs to 4.3% as labour market shows cracks By Proactive 19/03
Battery Metals Century Lithium feasibility study update boosts angel Island project economics, Noble says By Proactive 18/03
Hardware & electrical equipment Tech Bytes: Nvidia lifts AI demand outlook as inference shift reshapes infrastructure buildout By Proactive 18/03
